Sinopharm Group

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

China Pharmaceutical Market and Healthcare Industry Forecast and Analysis Report 2021-2025 - ResearchAndMarkets.com

Wednesday, August 4, 2021 - 12:03pm

The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has had quite an impact on the Chinese pharmaceutical and healthcare industry, through industry analysts expect a speedy recovery back to normal levels of demand.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • A SWOT analysis of the Chinese pharmaceutical and healthcare industry.

Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China

Monday, April 19, 2021 - 2:00pm

b'BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ --Citrine Medicine, aChina-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.

Key Points: 
  • b'BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ --Citrine Medicine, aChina-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.
  • "As a leading biopharmaceutical company in China, Citrine Medicine is working to introduce multiple innovative drugs to serve patients with rare diseases.
  • "\n"This new partnership with Sinopharm Group brings us closer to our vision of creating the very first rare disease ecosystem for patients in China," saidMelissa Bradford-Klug, President and Chief Business Officer of Citrine.
  • Our mission is to build the first rare disease ecosystem in China and in doing so, enable people with rare diseases to live more normal lives.

China Pharmaceutical Distribution Industry Report, 2019-2025 - ResearchAndMarkets.com

Monday, June 10, 2019 - 6:05pm

The "China Pharmaceutical Distribution Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Distribution Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • In China, a competitive pattern has taken shape that national drug distributors led by Sinopharm, China Resources Pharmaceutical Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional distribution companies such as Nanjing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun Pharmaceutical, Zhejiang Int'l Group, Realcan Pharmaceutical, Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each other.
  • The immense potential of the pharmaceutical distribution industry has attracted the inrush of capital in recent years, and mergers and acquisitions occurred frequently.
  • China Pharmaceutical Distribution Industry Report, 2019-2025 highlights the following:
    China pharmaceutical distribution industry (development environment, status quo, market size, market structure, competitive pattern and development trends)
    China drug retailing market (market size, gross margin, and net margin, quantity, the share of medical insurance designated stores, per customer transaction, and comparison of operating results between major drug retailers)
    20 Chinese pharmaceutical distribution companies (operation, revenue structure, gross margin, development strategy, etc.

Cedrus Investments Signed Cooperation Agreement with Sinopharm Nutraceuticals Industrial (Shanghai) on 16th November 2018

Wednesday, November 21, 2018 - 7:04am

SHANGHAI, Nov. 21, 2018 /PRNewswire/ -- Cedrus Investments ("Cedrus") , a global boutique investment firm, signed a cooperation agreement with Sinopharm Nutraceuticals Industrial (Shanghai) ("Sinopharm Nutraceuticals") on 16thNovember 2018 in Shanghai for the exploration and execution of investment opportunities in the pharmaceutical, healthcare and biotechnology industries by leveraging each other's strengths and resources.

Key Points: 
  • SHANGHAI, Nov. 21, 2018 /PRNewswire/ -- Cedrus Investments ("Cedrus") , a global boutique investment firm, signed a cooperation agreement with Sinopharm Nutraceuticals Industrial (Shanghai) ("Sinopharm Nutraceuticals") on 16thNovember 2018 in Shanghai for the exploration and execution of investment opportunities in the pharmaceutical, healthcare and biotechnology industries by leveraging each other's strengths and resources.
  • Sinopharm Nutraceuticals is an independent member of the Sinopharm Group, which is also one of its minority shareholders.The firm invests in new technologies and new medical care business models.
  • Cedrus' Chairman Mr. Rani Jarkas said, "I am excited to establish a long-term relationship with Sinopharm Nutraceuticals.
  • For further information about Cedrus Investments, please visit www.cedrusinvestments.com .